Mapping a patient’s journey through an Expanded Access Program (EAP) requires multi-dimensional perspective and foresight. At the outset of a program, consideration must be given to the patient experience continuum starting with enrollment in the EAP through to the patient’s transition to commercial product.
patient access before clinical trials
Development of specialty therapies is on the rise, especially for rare diseases, fueling an increase in patient awareness and advocacy. More often manufacturers are being asked to implement Expanded Access Programs (EAPs) while products conclude clinical trials. These programs set the tone for the relationship between the brand and the patient, making it critical to design the EAP with a variety of factors in mind. Download our free report that outlines key insights that every manufacturer should know about EAPs